SCHEMBL3097732

SCHEMBL3097732

CCN(C(=O)C(Cc1cnn(Cc2ccccc2Cl)c1)C(=O)NS(=O)(=O)C=Cc1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.36
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
ATM Q13315 1/20 0.33
TP53 P04637 1/20 0.33
LIMK1 P53667 1/20 0.32
LIMK2 P53671 1/20 0.32
KLKB1 P03952 1/20 0.32
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
SCD5 Q86SK9 1/20 0.31
HTT P42858 1/20 0.31
NR1H4 Q96RI1 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097720 1.00 POLB (0.36) POLBLMNAHPGDATMTP53
SCHEMBL3092554 0.92 HDAC2 (0.35) POLBLMNAALDH1A1SCD5HTT
SCHEMBL3092559 0.92 HDAC2 (0.35) POLBLMNAALDH1A1SCD5HTT
SCHEMBL3096804 0.91 HDAC2 (0.34) POLBHTTGAA
SCHEMBL3096793 0.91 HDAC2 (0.34) POLBHTTGAA
SCHEMBL3090317 0.89 HTT (0.35) POLBLMNAHPGDTP53ALDH1A1
SCHEMBL3090315 0.89 HTT (0.35) POLBLMNAHPGDTP53ALDH1A1
SCHEMBL3097471 0.89 LMNA (0.40) POLBLMNAHPGDALDH1A1MAPT
SCHEMBL3097463 0.89 LMNA (0.40) POLBLMNAHPGDALDH1A1MAPT
SCHEMBL3091894 0.88 SNCA (0.34) TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 POLB 4626/4885LMNA 3803/4885HPGD 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.